• Title/Summary/Keyword: Systemic administration

Search Result 445, Processing Time 0.023 seconds

A Study of the Effects of Systemic Skin Care as a Adjunct Treatment for Adult Atopic Dermatitis (피부 치료 시스템이 성인 아토피 피부염에 미치는 영향에 대한 조사 연구)

  • Song, Da-Hae
    • Journal of the Korean Society of Fashion and Beauty
    • /
    • v.3 no.3 s.3
    • /
    • pp.41-47
    • /
    • 2005
  • This study was conducted with 60 adult males who visited the Atomi Cooperative Clinic(Atomi Dermatology/Pediatrics/Oriental Clinic) in Seoul between May 2003 and December 2004; they were divided into three groups, each of which consisted of 20 persons, according to the level of erythma and then each group was subdivided to consist of ten according to whether they received skin treatment and care. The standard care provided to two groups involved topical steroids and oriental medicines prescribed by a dermatologist and a oriental doctor, respectively. 5th-grade topical steroid ointment was applied to the face and 3rd-grade to the limbs; a oriental medicine was administered in a lukewarm state half an hour after meals three times a day. To determine how special and systematic skin treatment and care was helpful in treating atopy, a skin treatment system was applied to the experimental group while the control group was provided with standard care alone. By using Mexameter(MX18) manufactured by ck-mpa as a measuring tool, the inflammation level was observed at the right antecubital space during each visit to the clinic. In view of the re suits, introduction of the systemic skin care for A. D to legitimate treatment provided by a medical institution is expected to be an appropriate supplementary treatment for adult patients who suffer from frequent recurrence of atopic dermatitis.

  • PDF

A COMPARATIVE STUDY ON THE PREDOMINANT CULTIVABLE MICROORGANISMS FOOLOWING THE APPLICATIONS OF E-PTFE AND COLLAGEN MEMBRANE AND THEIR ANTIBIOTIC SUSCEPTIBILITY TEST. (조직 재생유도술에 사용되는 e-PTFE 및 collagen막에 부착되는 치주세균과 항생제 감수성에 대한 연구)

  • Im, Hyo-Jeong;Kim, Surg-Jo;Choi, Jeom-Il
    • Journal of Periodontal and Implant Science
    • /
    • v.24 no.3
    • /
    • pp.561-571
    • /
    • 1994
  • The comparative study on the predominant cultivable periodontopathic bacteria were done 2 weeks after the application of the e-PTFE membrane and collagen membrane in the controlled tissue regeneration procedures. The purpose of the present study also included the antibiotic susceptibility test (ciprofloxacin, tetracycline, clindamycin) of these cultured organisms. 0.1% chlorhexidine mouthwash (10ml twice/day for 6 weeks) and systemic doxycycline (200mg/day for 2 weeks) were administered for supragingival and subgingival plaque control respectively. Four clinical isolates of A.a. from 2 patients were found to be resistant to tetracycline which were susceptible to clindamycin and ciprofloxacin. One isolate of W.r. and two unidcntified microorganisms were resistant only to clindamycin and one isolate of NID BPB and E.c. and two isolates of unidentified microorganisms were resistant only to ciprofloxacin. Overall susceptibility of tested microorganisms to ciprofloxacin, tetracycline and clindamycin were 85%, 77% and 89% respectively. The results indicated no significant differences in the percentage of cultivable periodontopathic bacteria between the two membranes, and also the microorganisms resistant to tetracycline after systemic administration of doxycycline turned out to be susceptible to either ciprofloxacin or clindamycin.

  • PDF

Systemic use of fluoroquinolone in children

  • Choi, Soo-Han;Kim, Eun Young;Kim, Yae-Jean
    • Clinical and Experimental Pediatrics
    • /
    • v.56 no.5
    • /
    • pp.196-201
    • /
    • 2013
  • Fluoroquinolones are an important class of antibiotics that are widely used in adult patients because of their broad spectrum of activity, good tissue penetration, and oral bioavailability. However, fluoroquinolone use in children is limited because juvenile animals developed arthropathy in previous experiments on fluoroquinolone use. Indications for fluoroquinolone use in patients younger than 18 years, as stated by the U.S. Food and Drug Administration, include treatment of complicated urinary tract infections and postexposure treatment for inhalation anthrax. In Korea, the systemic use of fluoroquinolones has not been approved in children younger than 18 years. Although concerns remain regarding the adverse musculoskeletal effects of fluoroquinolones in children, their use in the pediatric population has increased in many circumstances. While pediatricians should be aware of the indications and adverse effects of fluoroquinolones, recent studies have shown that the risk for musculoskeletal complications in children did not significantly increase following fluoroquinolone treatment. In addition, fluoroquinolones may be particularly helpful in treating multidrug-resistant infections that have not responded to standard antibiotic therapy in immunocompromised patients. In the present article, we provide an updated review on the safety and current recommendations for using fluoroquinolones in children.

Anti-histamic Effect and IL-4 and GM-CSF mRNA Expression on Sungmagalkun-tang (升麻葛根湯의 항히스타민 효과 및 IL-4와 GM-CSF 발현에 미치는 영향)

  • Kim, Hong-Bae;Kim, Own-Il;Lee, Seung-Yeon
    • The Journal of Pediatrics of Korean Medicine
    • /
    • v.20 no.1
    • /
    • pp.69-83
    • /
    • 2006
  • We investigated the effect of Sungmagalkun-tang (SGT) on the allergy. We conformed compound 48/80-induced active systemic anaphylatic shock, anti-dinitrophenyl IgE-mediated passive cutaneous anaphylaxis and ovalbumin-induced anaphylatic shock. Also observed IL-4 and GM-CSF mRNA expression in ovalbumin-induced allergic lung tissue and RBL-2H3. Histamine release is measured in RBL-2H3. SGT inhibited active systemic anaphylatic shock, passive cutaneous anaphylaxis and ovalbumin-induced anaphylatic shock by oral administration. We observed that SGT was concentration-dependently reduced IL-4 and GM-CSF mRNA expression in ovalbumin-induced allergic lung tissue and RBL-2H3 by SGT. In addition, SGT reduced histamine release in RBL-2H3. These results indicate that SGT has anti-histamic effect and controls IL-4 and GM-CSF mRNA expression on allergy.

  • PDF

Quantitative Assessment of Esophageal Movement Using Radionuclide in Patients with Systemic Sclerosis (전신성 공피증 환자에서 방사성 동위원소를 이용한 식도 운동의 정량적 측정)

  • Bom, Hee-Seung;Lee, Myung-Hae;Chung, June-Key;Lee, Myung-Chul;Choi, Sung-Jae;Song, In-Sung;Koh, Chang-Soon
    • The Korean Journal of Nuclear Medicine
    • /
    • v.21 no.1
    • /
    • pp.5-8
    • /
    • 1987
  • Nineteen patients with progressive systemic sclerosis were underwent radioisotope esophageal transit study (RIETS) which revealed abnormal transit time and/or pattern in 16 (84.2%). Among them 12 showed to and fro movement of RI and 4 showed retention of it. Abnormal esophageal transit was not related with Raynaud phenomenon. After intravenous administration of metoclopramide (10 mg), percent retention of RI in distal 2/3 of esophagus was significantly reduced (p<0.05).

  • PDF

Microbiological study of the antibacterial effects of locally delivered $Minocycline^R$ on the plaque accumulation on $Gore-tex^R$ membrane during the guided tissue regeneration therapy (치주조직유도재생술 시행시 Gore-tex 차폐막에 부착되는 치주세균에 대한 미노클린첨부제의 향균력에 대한 미생물학적 연구)

  • Choi, Jeom-Il;Ju, Ae-Ra
    • Journal of Periodontal and Implant Science
    • /
    • v.26 no.2
    • /
    • pp.356-364
    • /
    • 1996
  • The present study was done to evaluate the antibacterial effects of $Minoclin^R$ which was localally delivered on the $Gore-tex^R$ barrier membrane in the guided tissue regeneration(GTR) therapy for treatment of human furcal defects. Beneath the membranes. the antibiotics were applied for 1 week and then changed with new one. The $Minoclin^R$ was removed out one week later. 6 weeks after the GTR therapy. No systemic antibiotics were administered except for oral mouthrinses with chlorhexidines. 2 weeks and 6 weeks following the membrane therapy, the bacterial samples were examined for periodontopathic microorganisms. The results indicated that the locally delivered $Minoclin^R$ successfully inhibited the growth of periodontopathic organisms. This results might be further applied in the subgingival plaque control regimen in the GTR procedure, especialy in patients who is contraindicated for oral administration of systemic antibiotics

  • PDF

Antimicrobial Activities of LCB01-0183, a New Oxazolidinone (새로운 옥사졸리디논계 항균제 LCB01-0183의 항균 활성)

  • Lee, Hyun-Hee;Jung, Sung-Ji;Jeong, Ji-Woong;Cho, Young-Lag;Kim, Yong-Zu;Kwak, Jin-Hwan
    • YAKHAK HOEJI
    • /
    • v.57 no.2
    • /
    • pp.95-100
    • /
    • 2013
  • This study was performed to analyze in vitro and in vivo activities of LCB01-0183, a new oxazolidinone, against clinical isolates of bacteria. In vitro antibacterial activity of LCB01-0183 was tested by the two fold agar dilution method. In vivo activity of LCB01-0183 was determined against systemic infections in mice. LCB01-0183 showed most potent activity among the test compounds against clinical isolates of Gram-positive bacteria. Furthermore, the protective activity of LCB01-0183 was very effective against systemic infections in mice by oral or subcutaneous administration. In time kill study, LCB01-0183 showed a bacteriostatic activity during 24 hours. LCB01-0183 had potent in vitro and in vivo activity against Gram-positive bacteria including drug-resistant strains.

Identification of a Peptide Enhancing Mucosal and SystemicImmune Responses against EGFP after Oral Administration in Mice

  • Kim, Sae-Hae;Lee, Kyung-Yeol;Kim, Ju;Park, Seung-Moon;Park, Bong Kyun;Jang, Yong-Suk
    • Molecules and Cells
    • /
    • v.21 no.2
    • /
    • pp.244-250
    • /
    • 2006
  • Gangliosides are receptors for various peptides and proteins including neuropeptides, ${\beta}$-amyloid proteins, and prions. Recently, the role of gangliosides in mucosal immunization has attracted attention due to the emerging interest in oral vaccination. Ganglioside GM1 exists in abundance on the surface of the M cells of Peyer's patch, a well-known mucosal immunity induction site. In the present study we identified a peptide ligand for GM1 and tested whether it played a role in immune induction. GM1-binding peptides were selected from a phage-displayed dodecapeptide library and one peptide motif, GWKERLSSWNRF, was fused to the C-terminus of enhanced green fluorescent protein (EGFP). The fusion protein, but not EGFP fused with a control peptide, was concentrated around Peyer's patch after incubation in the lumen of the intestine ex vivo. Furthermore, oral feeding of the fusion protein but not control EGFP induced mucosal and systemic immune responses against EGFP resembling Th2-type immune responses.

Preparation and Evaluation of Solid lipid Microspheres Containing Cyclosporine A (사이클로스포린을 함유한 고형 지질미립구의 제조와 평가)

  • 양수근;박준상;최영욱
    • YAKHAK HOEJI
    • /
    • v.39 no.5
    • /
    • pp.487-494
    • /
    • 1995
  • Solid lipid microspheres (SLMs) were prepared using various lipids and solidifying agents, in order to enhance the gastrointestinal absorption of Cyclosporine A (Cs A) which is a practically water-insoluble drug with low systemic bioavailability. Egg lecithin and HCO-60 (polyoxyethylated 60 mol, hydrogenated castor oil) were used as lipids. Stearic acid and stearyl alcohol were used as solidifying agents. Emulsion concentrates containing Cs A were prepared by mixing the melted lipid and solidifying agent with water, employing bile salts as a cosurfactant. SLMs were obtained by dispersing the warm emulsion concentrate in cold distilled water under mechanical stirring, followed by freeze drying. Physical characteristics of each SLM were investigated by particle size analysis, optical microscopy and scanning electron microscopy. Mean particle size of SLMs was in the range of 30 to 40.mu.m. The SLMs were in good appearance with spherical shape before freeze drying, but were deformed partially after freeze drying. Drug loading efficiencies of SLMs were observed as high as 80 to 90% in average. The systemic bioavailability of Cs A from different SLM formula was investigated in rats following oral administration. Cs A in whole blood was extracted and assayed by HPLC. SLMs revealed the higher bioavailabilities than the standard formula based on the marketed product. SLMs might have several advantages over standard formula for enhanced gastrointestinal absorption, controlled release properties, high loading capacity of the water-insoluble drug, and feasibility of solid dosage forms with better stability in storage.

  • PDF

Antigenicity of a Water Soluble Dimethyl Dimethoxy Biphenylate Derivative(DDB-S), a New Antihepatitis Agent (새로운 간염치료제인 수용성 DDB 유도체 (DDB-S)의 항원성 평가)

  • Han, Hyung-Mee;Kim, Jin-Ho;Choi, Kyoung-Baek;Kim, Hyung-Soo;Chung, Seung-Tae;Moon, Jeon-Ok;Lee, Chi-Ho;Kim, Joo-Il
    • Toxicological Research
    • /
    • v.14 no.3
    • /
    • pp.307-313
    • /
    • 1998
  • Dimethyl dimethoxy biphenylate (DDB) is an agent used to treat hepatits. DDB-S (DDB-soluble), a new DDB derivative, was synthsized to increase water solubility of the original DDB. In the present study, the antigenic potential of DDB-S was examined by active systemic anaphylaxis (ASA), passive cutaneous anaphylaxis (PCA) and passive hemagglutination (PHA) tests. The experimental groups consist of a low dosage group, a high dosage group, he group emulsified with Freund's complete adjuvant (FCA, ASA test) or an alum (PCA and PHA tests) and the macromolecule conjugate group emulsified with FCA or an alum. In the ASA test, all experimental groups showed negative responses whereas the positive control group given ovalbumin plus FCA showed severe anaphylactic responses. In the heterologous PCA test using mice and rats, positive responses were not detected in any of the experimental groups. In the PHA test, all experimental groups showed negative responses whereas the positive control group given ovalbumin plus an alum showed 512~2048 PHA titers. These results demonstrated that DDB-S does not have any antigenic potential. These can be utilized as a part of preclinical data for the development of DDB-S as an intravenous injection.

  • PDF